TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 13 Best Revenue Growth Stocks to Buy Right Now.
On February 2, JPMorgan analyst Brian Cheng reduced the price target on TG Therapeutics to $46 from $49 while maintaining the Overweight rating on the shares. The investment bank had recently updated the model on the company.
TG Therapeutics presented its trial results on February 6 at a medical forum in San Diego, California. The presentation focused on the results of its Briumvi treatment for relapsing multiple sclerosis in adults.
Earlier, in mid-January, H.C. Wainwright analyst Emily Bodnar gave a Buy rating on the stock, citing the company’s strong commercial momentum and anticipated clinical catalysts in 2026. These include results for consolidated IV dosing and self-administered subcutaneous formulation for Briumvi, which could boost its market share against competing therapies.
On January 29, TD Cowen analyst Tara Bancroft reiterated a Buy rating on TG Therapeutics and set a $50 price target.
READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy.
This article is originally published at Insider Monkey.
